Welcome to Markets Desk, where we break down what's moving the tape and why it matters.
Target delivered a genuine beat this morning, topping Wall Street expectations on both revenue and earnings in its first quarter results. That's a meaningful signal for a retailer that's been navigating a cautious consumer environment, and it suggests the company's efforts to sharpen its merchandise mix and manage costs are beginning to show up in the numbers.
Shifting to pharma, the argument building around Merck is that investors are too focused on the eventual patent cliff facing Keytruda, the company's blockbuster cancer therapy, and not enough on the pipeline being assembled to replace that revenue. The case here is that Merck has more runway and more optionality than its current valuation implies, making it a potentially undervalued long-duration hold.
And in the AI space, the debate is sharpening between momentum buyers and valuation skeptics. Meta Platforms keeps surfacing as the name analysts point to when arguing that not every AI-adjacent stock is dangerously overpriced. Its earnings power relative to peers suggests there's still a credible entry point, even after a substantial run.
That's the tape. Markets Desk, signing off the floor.
